Pomdoctor regains compliance with Nasdaq minimum bid price requirement
POM•Pomdoctor regained compliance with Nasdaq’s $1 minimum bid price requirement, and Nasdaq confirmed the shares would remain listed. The delisting hearing scheduled for November 12, 2026, was canceled.
1. Listing compliance restored
Pomdoctor said Nasdaq confirmed on November 5, 2026, that it had regained compliance with the $1 minimum bid price requirement under Listing Rule 5450(a)(1). Its Class A ordinary shares will remain listed under POM, and a November 12 delisting hearing was canceled. Nasdaq’s October 6 determination followed 30 consecutive business days with closing bid prices below $1 per share.
